Clinical Research Currents
  • Home
  • About Us
  • News
    • AI & Machine Learning
    • Alzheimers & Dementia
    • Animal studies
    • Clinical development
    • Clinical science
    • Contract Research Organization
    • Disparities
    • Education
    • Employment
    • FDA
    • FDA Guidance
    • FDA Guidance Documents
    • History
    • Immunotherapy
    • Innovation
    • International
    • Interview
    • Investigator
    • Mobile
    • NIH
    • Operations
    • Patient Perspective
    • Political economy
    • Pre-clinical
    • Precision Medicine
    • Recruitment
    • Regulatory
    • Study Design
    • Wearables
    • Trends
    • Real World Data/Evidence
    • Blockchain
    • Clinical trials
    • Adverse events
    • Technology
  • Calendar
  • Newsletter
  • Resources

2021 Update

Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.

Biocom program “Zika Virus and Emerging Diseases” highlights importance of public-private collaboration

October 24, 2016 Leave a Comment

by Marie Jung

BioCom’s October 13th Breakfast Meeting on “Zika Virus and Emerging Diseases” was not one to be missed, but in case you had something else going on, Clinical Currents is here to update you.

The talk was sponsored by DLA Piper, and was led by Karen Midthun, M.D., an Infectious Diseases specialist and former director of the FDA’s Center for Biologics Evaluation and Research (CBER). Due to its major relevancy in the news, the Zika virus and the search for its cure had attracted many individuals. There were a variety of guests attending the breakfast meeting from a diverse set of fields like engineering consulting, life science insurance, and animal health, among others. The atmosphere, as well as the talk itself, had a major focus on the synthesis of biology and business, and the responsible applications of both.

The outline presented by the esteemed Dr. Midthun included the role of government in countermeasures, an analysis of similar public health issues through case studies, the need for collaboration of the public and private sectors, and a look towards the future on how society can do better when it comes to these outbreaks.

A lot of the speech was directed towards government policies towards infectious diseases, and also how the private sector could help by supplementing funding and support. Solutions included a change in framework, specialization of approaches based on individual epidemiology of outbreaks and using a multifaceted approach (such as genetically modified mosquitos). Dr. Midthun called for better inter and intra governmental collaboration as means for addressing epidemics, as well as increasing speed in developments of technical aspects of development and regulation.

Share this:

  • Facebook
  • Twitter
  • LinkedIn

Filed Under: Clinical development, FDA Guidance, Regulatory

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Subscribe to our Newsletter

Get the latest clinical research news delivered straight to your inbox each week.

Submit a Story

Do you have a story you'd like to feature on our website? Share it with us today!

Submit your story

 Join our LinkedIn Group

© 2022 Clinical Research Currents · All Rights Reserved